AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
menatetrenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonists | 1685 | 863-61-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 0.23 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ULK2 | 62 | |||
| kinase-selectivity-class | AXL,BRAF,CDK4,EIF2AK3,GRK2,MAP2K6,STK33,TEK,TTK | 9 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral infarction | 41.63 | 26.86 | 16 | 1521 | 26580 | 90600330 |
| Hepatic function abnormal | 39.27 | 26.86 | 18 | 1519 | 46270 | 90580640 |
| Disseminated intravascular coagulation | 30.31 | 26.86 | 12 | 1525 | 21526 | 90605384 |
| Platelet count decreased | 29.91 | 26.86 | 22 | 1515 | 136947 | 90489963 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral haemorrhage | 74.41 | 29.12 | 31 | 1155 | 38935 | 42581214 |
| Cerebral infarction | 37.58 | 29.12 | 18 | 1168 | 31151 | 42588998 |
| Hepatic function abnormal | 36.95 | 29.12 | 21 | 1165 | 51546 | 42568603 |
| Thalamus haemorrhage | 30.96 | 29.12 | 7 | 1179 | 1112 | 42619037 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral haemorrhage | 88.94 | 23.53 | 40 | 2805 | 64928 | 110521526 |
| Cerebral infarction | 77.63 | 23.53 | 34 | 2811 | 51804 | 110534650 |
| Hepatic function abnormal | 71.15 | 23.53 | 38 | 2807 | 89257 | 110497197 |
| Disseminated intravascular coagulation | 48.88 | 23.53 | 23 | 2822 | 41263 | 110545191 |
| Platelet count decreased | 44.43 | 23.53 | 41 | 2804 | 230402 | 110356052 |
| Brain herniation | 39.82 | 23.53 | 13 | 2832 | 8850 | 110577604 |
| Thalamus haemorrhage | 37.71 | 23.53 | 9 | 2836 | 1955 | 110584499 |
| Altered state of consciousness | 36.22 | 23.53 | 21 | 2824 | 57605 | 110528849 |
| Embolic stroke | 32.03 | 23.53 | 11 | 2834 | 8732 | 110577722 |
| Pneumonia | 31.09 | 23.53 | 69 | 2776 | 876645 | 109709809 |
| Upper respiratory tract inflammation | 30.57 | 23.53 | 9 | 2836 | 4362 | 110582092 |
| Renal impairment | 29.64 | 23.53 | 30 | 2815 | 188415 | 110398039 |
| Serum ferritin increased | 28.77 | 23.53 | 11 | 2834 | 11836 | 110574618 |
| Pneumonia aspiration | 27.32 | 23.53 | 20 | 2825 | 81213 | 110505241 |
| Brain oedema | 26.90 | 23.53 | 14 | 2831 | 31084 | 110555370 |
| Pyrexia | 24.60 | 23.53 | 64 | 2781 | 898201 | 109688253 |
| Putamen haemorrhage | 24.40 | 23.53 | 5 | 2840 | 540 | 110585914 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M05BX08 | MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Other drugs affecting bone structure and mineralization |
| MeSH PA | D003029 | Coagulants |
| MeSH PA | D006401 | Hematologic Agents |
| MeSH PA | D006490 | Hemostatics |
| MeSH PA | D000933 | Antifibrinolytic Agents |
| MeSH PA | D014815 | Vitamins |
| MeSH PA | D018977 | Micronutrients |
| CHEBI has role | CHEBI:22586 | antioxidant |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50646 | bone density conservation agent |
| CHEBI has role | CHEBI:63726 | neuroprotective agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:77746 | human metabolite |
Related Drugs by ATC class:
M05BX Other drugs affecting bone structure and mineralization 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hemorrhagic disease of the newborn due to vitamin K deficiency | indication | 12546009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-synuclein | Transporter | IC50 | 4.82 | CHEMBL | |||||
| Cruzipain | Enzyme | IC50 | 4.74 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D00100 | KEGG_DRUG |
| C0065936 | UMLSCUI |
| CHEBI:16374 | CHEBI |
| 1L3 | PDB_CHEM_ID |
| CHEMBL259223 | ChEMBL_ID |
| CHEMBL5314971 | ChEMBL_ID |
| DB12148 | DRUGBANK_ID |
| C030814 | MESH_SUPPLEMENTAL_RECORD_UI |
| 3292 | INN_ID |
| 27Y876D139 | UNII |
| 5282367 | PUBCHEM_CID |
| DB14936 | DRUGBANK_ID |
| 29495 | RXNORM |
| 337527 | MMSL |
| 35482 | MMSL |
| 37263 | MMSL |
| d09345 | MMSL |
| 012756 | NDDF |
| 013766 | NDDF |
| 22606007 | SNOMEDCT_US |
| 712684001 | SNOMEDCT_US |
| D024482 | MESH_DESCRIPTOR_UI |
| 2771 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
None